Baird Maintains Outperform on Eiger BioPharmaceuticals, Raises Price Target to $5
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Brian Skorney maintains an Outperform rating on Eiger BioPharmaceuticals (NASDAQ:EIGR) and raises the price target from $3 to $5.
June 30, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst has maintained an Outperform rating on Eiger BioPharmaceuticals and raised the price target from $3 to $5.
The news of Baird maintaining an Outperform rating and raising the price target for Eiger BioPharmaceuticals is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100